Accelerate Recovery Time from
Strenuous Workouts and Sports Injuries
Flavay® has been licensed and sold in France for treating
inflammation and edema (swelling) since 1950 and is now available
in the United States as a dietary supplement. Research shows
several ways that Flavay® can help minimize damage and
accelerate recovery time from strenuous workouts and sports-related
activities.
Flavay’s® action is synergistic for athletes: it protects
the body by helping neutralize the naturally occurring pro-oxidative
effects of strenuous workouts, and strengthens the body’s
collagen, which is a major component of muscles, tendons, cartilage,
ligaments and bones.
Flavay’s® ability to strengthen and rebuild collagen is
important to injury-recovery because most athletic injuries
involve damaged capillaries (tiny blood vessels), caused by
torn muscles, sprains, fractures or twisting and whiplash. Strengthening
of the vascular walls in the capillaries prevents fluids from
seeping and swelling in the connective tissues. These types
of injuries are painful and usually cause other problems, such
as a loss in physical condition when the injury causes an inability
to train or compete.
Research has shown that Flavay’s® ability to strengthen
vascular walls may help the body to repair injuries faster.
In an Australian study conducted on two groups of soccer players
that had sustained injuries, those that consumed Flavay®
for ten days following their injuries experienced significantly
less swelling than those who did not and, in some of those taking
Flavay®, the swelling had completely disappeared. Other
research has demonstrated the ways in which Flavay® may
actually inhibit inflammation including double-blind studies
conducted in France which showed that Flavay® can also
reduce postoperative inflammation.
Natural Anti-Inflammatory
Inflammation is caused by the overproduction of free radicals
in a specific area of the body. We now know that antioxidants
work together to defeat free radicals and inhibit the biological
pathway that triggers inflammation, and Flavay® is particularlyeffective as an anti-inflammatory.
Flavay® can selectively bind to the connective tissue
of joints, preventing inflammation and lessening pain. One of
the very first benefits observed and studied Dr. Jack Masquelier,
in as early as 1947, was the anti-inflammatory effect of Flavay®.
Research demonstrates that Flavay® inhibits the release
and synthesis of histamine (which produces accelerated blood
flow, dilates capillaries and increases their permeability,
thereby leaking plasma into surrounding tissue), a key factor
in the promotion of inflammation.
Studies demonstrate that the anti-histamine action of Flavay®
is obtained through inhibiting the activity of the enzyme histidine
decarboxylase. Dr. Masquelier’s research has been confirmed
by German studies which show that Flavay® may lower the
production of histamine with as much as 86% inhibition of histidine
decarboxylase.
Flavay® also neutralizes free radicals that promote swelling
and cause inflammation. A free radical called superoxide is
involved in the inflammation of arthritis and several experiments
show that Flavay® quenches the superoxide free radicals.
"Radical Scavenger Effect"
of Flavay®
Protected by U.S. Patent No. 4,698,360
Flavay® is a strong antioxidant that is patented as a
scavenger of the free radicals that play a major role
in the initiation, duration and breakdown of inflammation.
"[A] method for preventing and fighting
the harmful biological effects of free radicals
in the organism of warm blooded animals and more especially
human beings, namely cerebral involution, hypoxia following
atherosclerosis, cardiac or cerebral infarction, tumour
promotion, inflammation, ischaemia, alterations
of the synovial liquid, collagen degradation, among
others. The method consists in administering to said
animals and especially to human beings an amount, efficient
against said effects, of a plant extract with a proanthocyanidins
content which has a radical scavenger effect"—Dr.
Jack Masquelier, U.S. Patent No. 4,698,360.
Flavay® is the actual product—used in the experiments—by
which Dr. Jack Masquelier established and patented the "radical
scavenger effect."
Sports and Exercise Increase
the Body's Need for Antioxidants
Exercise is extremely beneficial, but many do not realize that
exercise increases the body's need for antioxidants. The fuel
our bodies require for sports and exercise is oxygen. Yet the
body's production of energy from oxygen can also wreak havoc
in the body because it produces free radicals. If we are deficient
in antioxidants, the benefits of exercise are diminished by
the damage caused by free radicals. Thus, the key to good health,
is to maintain the right balance between antioxidants
and free radicals. It's not surprising, therefore, that studies
have suggested that antioxidants like Flavay® can actually
improve athletic performance and endurance.
Superior Antioxidant Support
Flavay® is superior to other antioxidants because its
protective effects are multiplied in the body. While it provides
its own, powerful antioxidant protection, it also supports the
dynamic interplay between other antioxidants in the body. Flavay's
ability to “recycle,” or regenerate vitamins C and
E after they have quenched free radicals vastly extends their
unique antioxidant powers, helping to maintain an optimal, synergistic
antioxidant balance in the body.
Flavay® is rapidly absorbed and very quickly distributed
throughout the body. As a free radical fighter, Flavay®
comes to the aid of the body more quickly than other antioxidants,
reducing the potential for free radical damage and the ravages
of aging. Flavay® also possesses more reactive sites for
neutralizing free radicals than other known antioxidants. Furthermore,
Flavay® permits reactivity with both positively and negatively
charged free radical species. What this means is that Flavay®
can “quench” or “scavenge” (neutralize)
a broad variety of free radicals. Highly reactive as an antioxidant
in both lipid (fat) and aqueous (water) phases, Flavay®
neutralizes oxygen free radicals and is a valuable protector
of healthy cells in a variety of internal conditions. This is
a unique property among antioxidants, as most work either in
lipid or aqueous phases, but not both. Research shows that Flavay®
can regulate nitric oxide and quench superoxide and the hydroxyl
radical. This is extremely important. Of all the free radicals
formed in the body, the hydroxyl radical is the most dangerous
because it can directly attack DNA. As a free radical scavenger,
Flavay® is like an antioxidant prize fighter that can
successfully take on all challengers, big or small, in any kind
of weather.
Proven Safety of Flavay®
After more than 50 years of human use, no adverse effects have been observed.
Furthermore, intensive biological, toxicological, pharmacological and analytical
research was conducted for the purpose of registering it as a medicine in France
and other countries in Europe. In one study, daily doses of up to 35,000 mg
for six months were determined to cause no adverse effects. Flavay® was
also clinically tested, in particular for all sorts of symptoms related to venolymphatic
insufficiencies (strenghthening veins, improving circulation and reducing edema
and inflammations). The spin-off is a goldmine of data: The rigorous testing
to meet the standards required by the health ministries of France, Germany and
other European countries demonstrate that Flavay® is highly bioavailable,
nontoxic, nonallergenic, noncarcinogenic, nonmutagenic, will not cause birth
defects, and is completely safe.
Dr. Masquelier’s unequaled manufacturing process has been conducted
for half a century at the very same facilities in France, and under the
control of French Pharmaceutical inspection. These time-proven standards
serve as a reliable assurance of the quality, consistency, bioavailability
and safety of Flavay®.
Who can take Flavay®?
Everyone, from the very young to elderly. Flavay® has no known contraindications
(conditions under which it should not be used). Flavay® is completely safe
and nontoxic. In fact, clinical trials have been conducted in which pregnant
women (troubled by varicose veins and other circulatory problems in the
legs) safely used Flavay®.
Why Trust Flavay®
Consumers need to know that the marketplace is full of imitations, various
“extracts” and derivative forms of Dr. Masquelier’s scientifically
proven and patented complex. Unfortunately, many have even used Dr. Masquelier’s
name and research in unauthorized ways to promote illegitimate products.
Flavay® is the name you can trust for the precisely
defined active polyphenol complex patented and perfected by the inventor, Dr.
Jack Masquelier, validated by the French Ministry of Health and documented by
a library of research consisting of many patents and hundreds of scientific
papers, articles, doctorate theses, lectures and presentations. For quality,
consistency, bioavailablity and safety, consumers may rely upon Flavay®.
Statements made herein have not been
evaluated by the Food and Drug Administration. These products are not intended
to diagnose, treat, cure or prevent any disease.
Masquelier, J. Plant extract
with a proanthocyanidins content as a therapeutic agent having
radical scavenging effect and use thereof. U.S. Patent No. 4,698,360,
1987.
Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa
Omega Editrice, Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice,
Publishers, 1995.
Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats
Publishing, Inc., 1997.
Packer, L., et al. The antioxidant miracle: your complete plan.
John Wiley & Sons, Inc., 1999.
Packer, L., et al. Antioxidant food supplements in human health.
Academic Press, 1999.
Lincoln, J., Hoyle, C.H.V., Burnstock, G., Nitric oxide in health
and disease. Cambridge University Press, 1997.
Moncada, S., Nistico, G., Bagetta, G., Higgs, E.A. Nitric oxide
and the cell. Princeton University Press, 1998.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme
activities of procyanidines from vitis vinifera. A mechanism for
their capillary protective action. Arzneimittelforschung, 44:
592-601, 1994.
Passwater, R.A. The antioxidants: the nutrients that guard your
body. Keats Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants.
Keats Publishing, Inc., 1995.
Facino RM, et al. Free radical scavenging action and anti-enzyme
activities of procyanidines from Vitis vinifera. A mechanism for
their capillary protective action. Arzneimittelforschung, 44:
592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant
to the action of mammalian collagenase. Experientia, 37: 221-223,
1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres
procyanidoliques. Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides.
A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques
totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques.
Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action
des oligomeres procyanidoliques sur des cellules mesenchymateuses
en culture. Ii l’attachment des fibres elastiques aux cellules.
(Study of the effect of procyanidolic oligomers on mesenchymal
cells in culture. Ii attachment of elastic fibers to the cells.)
Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular
and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin
[(2r,3s,+r)-(+)-3,3’, 4.4’, 5.7’-Hexahydroxyflavan]
dihydrate, and comparison of its heterocyclic ring conformation
in solution and the solid state. Journal of the Chemical Society;
Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free
radicals. Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins
b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem,
54(10) 1990. pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different
procyanidins from grape seeds. Presented at a symposium, “Free
radicals in biotechnology and medicine.” Royal Society Of
Chemistry, London January 1990, pp. 79-80.
Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase
durch flavonoide und phenolderivate im vergleich nit deren 02
radikalfangereigenschaften” Arch Pharm, (Weinheim) 313 (1980)
pp. 330-337.
Lombard, J., et al. The brain wellness plan. Kensington Pub. Corp.,
1998.
Flesch M., et al., Effects of red and white wine on endothelium-dependent
vasorelaxation of rat aorta and human coronary arteries. Am J
Physiol 1998;275:1183-94.
Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM.
Isolation and characterization of endothelium-dependent vasorelaxing
compounds from grape seeds. J Agr & Food Chem In press.
Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation,
endothelium, and wine. BioFactors 1997;6:455-459.
Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey
RG. Endothelium-dependent vasorelaxation caused by various plant
extracts. J Cardiovasc Pharmacol 1995;26:90-95.
Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent
vasorelaxing activity of wine and other grape products. Amer J
Physiol 1993;265:H774-H778.
Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with
catechin becomes resistant to the action of mammalian collagenase.
Experientia, 37: 221-223, 1981.
Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95:
89-97, 1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies
that binding of pycnogenols to elastin affects its rate of degradation
by elastases. Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985.
Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers
extracted from ‘vitus vinifera l.’ in the rat. European
Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1
pp. 15-30.
Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging
activity of proanthocyanidolic oligomers encapsulated in glycospheres:
an in vivo and in vitro study. Cosmetology Department & S
Biovectors, Ramonville St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i
converting enzyme by flavanolic compounds: in vitro and in vivo
studies. Planta Medica, May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex
Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-activite aniagoniste vis-a-vis des mediateurs
de l’inflamation. Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire,
spontanement ou artificiellement diminuee par l’action d’une
substance capillaro-toxique chez des personnes agees--action benefique
d’un agnet actif sur la micro-circulation: l’Endotelon.
Inform. Therapeut. 1980. pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude
d’un microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7,
1990.
Lagrue, G., Olivier-Martin, F., Grillot, A. “Etude des effets
des oligomeres du procyanidol sur las resistance capillaire dand
l’hypertension arterielle et certaines nephropathies.”
Sen. Hosp. Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur
peripherique, l’Endotelon. Actualite Therapeutique Gaz. Med.
de France (87)22:2919-24, 1980.
Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice
de fragilite capillaire dan une population specifique: les sujets
cirrhotiques. Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres
inferieurs par un microangioprotecteur l’Endotelon. Bordeaux
Med, 11:685-8, 1981.
Delacroix, P. Etude en double aveugle de l’Endotelon dans
l’insuffisance veineuse chronique. Therapeutique, la Revue
de Medicine, (27-28) Sept. 1981. pp. 1793-1802.
Thebaut, J.F, Thebaut, P., Vin, F. Etude de l’Endotelon dand
les manifestations fonctionnelles de l’insuffisance veineuse
peripherique-resultats d’une etude en double aveugle portant
sur 92 patients.” Gazette Medicale, (92)1, 1985. pp. 96-100.
Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and
arachidonate metabolism in platelets by procyanidins. Prostagland
Leukotri Essent Fatty Acids, 38:181-8, 1989.
Masquelier, J. Pycnogenols: recent advances in the therapeutical
activity of procyanidins. Supplement of Planta Medica, Journal
of Medicinal Plant Research and Journal of Natural Products, July
1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury:
implications in atherosclerosis. Free Rad Path & Med, (4)1988
pp. 99-106.
Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.”
pp. 88-93.
Gazave, J.M. “Notions recentes sur les capillaires”
unpub. bulletin from the Laboratoire De Physiologie Patholigie
pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation
and atherothrombosis. Office International Vigne et du Vin, Nutrition
and Health Unit, Paris France; Drugs under Experimental and Clinical
Research (Switz.) 25/2-3 (125-131), 1999.
Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin.
Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240,
1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase.
Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie.
Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P “Une Etude Exemplaire Pour Un Phlebotrope: l’etude
EIVE.’ Unpub., pp. 77-83.
Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon
decobaye. Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated
with (+) -catechin becomes resistant to the action of mammalian
collagenase.” Laboratory of Connective Tissue Research, Dept.
of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des
oligomeres procyanidoliques sur le lathyrisme experimental chez
le rat.” Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal
circulation. Study of the effect of procyanidolic oligomer (Endotelon).
Jn. Fr. Opthalmol, (11)5:453-460, 1988.
Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and
dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol
Fr, 88(2):173-4, 177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside
oligomers effects on retinal function in myopic subjects. Ann
Ott Clin Ocul, 114:85-93, 1988.
Saracco, J.B., Estachy, G.M. Etude d l’Endotelon en opthalmologie.
Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies.
Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol,
11:453, 1988.
Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C.
Bordeaux Medicale, (16)11. pp. 1467-74, 1978.
Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology.
Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. “Les oligomeres procyanidoliques dans le traitement
de la fragilite capillaire et de la retinopathie chez les diabetiques.
A propos de 26 cas.” Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques:
Endotelon, dans la retinopathie diabetique (a propos de 30 observations).
Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results
of a double-blind study versus placebo in 32 female patients.
Ann Chir Plast Esthet 29(4):393-5, 1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism
in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62,
1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels.
Angiologica, 9:355-374, 1972.
Havsteen, B. Flavonoids, a class of natural products of high pharmacological
potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer,
H.J. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger.,
1977.
Masquelier, J. Action protectrice du vin sur l’ulcere gastrique.
Resultats, p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by
flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985.
Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®]
Helps Sports People.
Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums
Cosmet Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques
(Endotelon) dans le traitement des lymphoedemes post-therepeutiques
de members superieurs. Symposium Satellite, Congres International
d’Angiologie, Toulouse, France, 4-7 Oct. 1989.
Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during
2 weeks of intense training. Abstract submitted to national meeting
of the Amer College of Sports Medicine, June 1998.
Monteleone, P., Maj, M., Beinat, L., Natale, M., Kemali, D. Blunting
by chronic phosphatidylserine administration of the stress-induced
activation of the hypothalamo-pituitary-adrenal axis in healthy
men. Eur J Clin Pharm 43: 385–388, 1992.
Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine
administration during two weeks of resistive exercise-induced
overtraining. Bio of Sport 15(3):135-44, 1998.
Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres
procyanidoliques sur le cobaye carence en vitamin c. Tavaux Originaux,
University of Bordeaux, 1976.
Masquelier, J. Action comparee de divers facteurs vitaminiques
p sur l’oxydation de l’acide ascorbique par les ions
cuivriques. Bull. de la Societe de Chimie Biologique XXXIII (3-4)
1951. pp. 302-304.
Masquelier, J. Action comparee de divers facteurs vitaminiques
p sur l’acide ascorbique-oxydase. Bull. de la Societe de
Chimie Biologique XXXIII (3,4) 1951. pp.304-306
Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G.,
Mishioka, I. “Inhibitory effects of tannins on hyaluronidase
activation and on the degranulation from rat mesentery mast cells.”
Chem. Pharm. Bull. 33(11)1985. 5079-5082.
Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J.
“Histamine and acute haemorrhagic lesions in rat gastric
mucosa: prevention of stress ulcer formulation by (+)-catechin,
an inhibitor of specific histidine decarboxylase in vitro.”
Dirkhauser Verlag,Vol. 7/1, 1977.
Pariente, J.J. Parientl-Amsellem, J. “Les oedemes post-traumatoqies
chez le sportif: essai controle de l’Endothelon.” Actualite
Therapeutique 90(3) 2/11 1983 pp. 231-235.
Masquelier, J., et al. “Flavonoids et Pycnogenols” Int
J Vit Nut Res, (49)3:307-311, 1979.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem.
Toxicol. 25(2):135-9, 1987.
Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica
Report, 1971.
Laparra, J., et al., Acta Therapeutica, 4:233, 1978.
Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow
cells of the mouse with Pycnogenol. Cytotest Cell Research GmbH
& Co., projects 143010 & 143021; Feb. 1989.
Acute and chronic toxicity tests. International Bio-Research,
Inc., Hanover, Germany, 1967-1971.
Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content
in vegetable extracts to be used in the preparation of medicines.
Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.
